|Head and Neck Cancers: The Basics|
|Carolyn Vachani, RN, MSN, AOCN|
|Abramson Cancer Center of the University of Pennsylvania|
| Last Modified: January 21, 2010
What is the "head and neck"?
This may seem like a silly question to address, but it is important when talking about head and neck cancers that you understand exactly which areas the cancer includes. The pharynx is a tube about 5 inches long, extending from the back of the nose to the area where the esophagus (tube to the stomach) and the trachea (tube to the lungs) both begin. In terms of head and neck cancers, the pharynx and the surrounding structures are divided into several areas:
This graphic is looking at a head that is cut down the center.
What are head and neck cancers?
In the United States, there will be an estimated 47,500 new cases of head and neck cancer (HNCA) in 2008, with 11,200 people dying from the disease. Globally, there are an estimated 533,100 new cases a year, and it is the fifth most common cancer worldwide. In contrast, HNCA does not rank in the top 10 in the US, accounting for only 3% of all cancers. The variations in rates around the world are a result of differences in dietary and tobacco habits, alcohol use, and viral and environmental exposures.
You can see that this category encompasses quite a few different cancers. All cancers begin when abnormal cells in a part of the body begin to grow in an out-of-control manner. That is about where the similarities end, as different cancer types are treated in different ways, and head and neck cancers are no exception. This is an introductory article, so you may need to use the links on the left to get more detailed information on specific types of head and neck cancer.
What are the causes of head and neck cancer, and am I at risk?
It is estimated that 80-90% of all head and neck are caused by tobacco and alcohol use. Tobacco includes cigarettes, cigars, pipes, and smokeless tobacco (chew, dip, snuff, and betel quid). Tobacco users are between 20-40 times more likely to develop head and neck cancer than non-smokers, depending on the amount of use, as well as the age, sex and race of the user. Smoking more than 4 cigarettes a day increases the risk to 20 times that of a non-smoker. The composition of smokeless tobacco varies around the world, making it hard to generalize, but the risk of developing head and neck cancer is thought to be 1-10 times more for smokeless users than non-users. Quitting smoking leads to a reduction of risk that increases with time, but will never reach that of a never-smoker.
Drinking alcohol is known to increase the risk of developing head and neck cancer about 2-10 times that of non-drinkers, depending on the amount consumed. Alcohol use alone increases risk, but when combined with tobacco, the risk increases dramatically. Some researchers believe alcohol may make the tissues more susceptible to damage from the toxins in tobacco.
Men develop head and neck cancer twice as often as women in the United States, and make up 68% of all cases and 71% of the deaths from this disease. For example, in cancer of the tongue specifically, roughly 1,200 men will be diagnosed this year, versus only about 670 women. As people age, their risk increases, and most cases are diagnosed in people over age 65. African-American and Asian individuals are at higher risk for all types of head and neck cancers. Although oral and pharyngeal cancers have decreased over the last 20 years among white males and females under age 65 and in black women of all ages, it has increased in black males.
Infection with certain strains of the Human Papilloma Virus (HPV), a sexually transmitted disease that invades human epithelial tissue (a type of skin cell), is known to increase risk of oropharyngeal cancers. It is estimated that 5.5 million people worldwide are infected with this virus annually. Sexually active individuals have an 80 to 85% chance of being infected at some time in their life. Researchers estimate that 50% of oropharyngeal cancers are attributable to HPV, with a much higher rate in young non-smokers diagnosed with the disease. This is thought to be related to changes in sexual practices, including an increase in oral sex among adolescents and young adults. Despite the decrease in smoking-related cancers in the U.S., this HPV-related increase has the potential to become a serious public health burden.
Rates of nasopharyngeal cancers in Asian countries are high and thought to be a result of a diet high in salt-cured foods. Chronic sun exposure is linked to cancer of the lip. Exposure to asbestos is thought to increase the risk of laryngeal cancers. Inactive infection with the Epstein Barr virus (EBV), environmental or second-hand smoke, and the chronic inhalation of wood dust have all also been associated with increased risk of head and neck cancers.
What are the signs of head & neck cancers?
The signs and symptoms can vary greatly depending on the location of the tumor. Some common symptoms are weight loss (due to difficulty swallowing and/or malnutrition), a new lump or sore that does not resolve, a sore throat or change in voice that doesn't get better, or pain (sometimes felt in the ear). More specific signs include the following:
How are head and neck cancers diagnosed and staged?
If a head and neck cancer is suspected, a physician will perform a thorough examination of the head and neck, both inside and out. This requires the use of an endoscope, a thin tube with a camera on the end that is inserted in the nose or down the throat after numbing the patient's nose, throat and gag reflex. This is necessary to either evaluate the lesion or lump in question, or to look for any additional lumps. A sample of the tissue in question and/or other suspicious areas will be taken (biopsy). Depending on the location, this may be done in the office, or if it is not accessible, may need to be done in an operating room. A pathologist, a doctor who looks at the sample under a microscope and determines the type of cell and whether or not it is cancerous, evaluates the biopsy.
About 95% of head and neck tumors are squamous cell carcinomas (named for the type of cells that the cancer involves). Some other types include: adenocarcinoma, mucoepidermoid carcinoma, adenoid cystic carcinoma, acinic cell carcinoma or other malignant salivary tumors, lymphoma, sarcoma and melanoma.
Computerized tomography (CAT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans are an important step to further evaluate the tumor and to determine the stage and options for treatment.
Staging is done by evaluating tumor size (T), lymph node involvement (N), and metastases (M), or spread to other areas of the body. Although you may sometimes hear the cancer described as stage I, II, etc.; the TNM system is more precise in this group of very diverse tumors. The following gives you an understanding of TNM definitions and the corresponding stage. Keep in mind, the staging system is even more complex for each particular site, but these general TNM descriptions can be applied to all head and neck tumors.
Primary Tumor (T)
TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor
Tis: "insitu" – cancer contained
T1: Tumor 2 cm or less in size
T2: Tumor > 2 cm but < 4 cm in size
T3: Tumor > 4 cm in size
T4a: Tumor invades structures next to it
T4b: Tumor invades to areas beyond the structures next to it
Regional Lymph Nodes (N)
NX: Regional nodes cannot be assessed or unknown
N0: No regional lymph node metastasis
N1: Metastasis in 1 lymph node on the same side as the tumor, < 3 cm in size
N2: Metastases in 1 or more nodes on same, opposite, or both sides, between 3-6 cm in size
N3: Metastases in 1 or more nodes, > 6 cm in size
Distant Metastasis (M)
MX: Distant metastasis cannot be assessed
M0: No distant metastasis
M1: Distant metastasis
How are head and neck cancers treated?
Head and neck cancers are best treated by multidisciplinary cancer care teams. This team of specialists may include oral surgeons, otorhinolaryngologists (ENT), pathologists, medical and radiation oncologists, dentists, plastic surgeons, dietitians, social workers, nurses, physical and speech therapists. This team approach is very important to successful treatment and to helping maintain good patient quality of life. The actual treatment plan varies depending on the tumor location, stage, and patient's baseline medical health (i.e. how much treatment can they handle?).
In general, stage I and II cancers are treated with surgery and/or radiation therapy, whereas stages III and IV require multi-modality treatment (surgery, radiation, and chemotherapy). The following are the basic therapies used in the treatment of head and neck cancer.
In determining whether or not a patient should have surgery, it is extremely important to look at his or her physical health. For example, a patient with very poor nutrition will have difficulty healing from surgery. Heart disease or pulmonary (lung) problems may make him or her unable to tolerate the operation. We do not want to put the patient in further danger in these cases. The second issue is, can the tumor be safely removed by the surgeon? This depends on where it is located, what other structures it invades, and the size of the tumor. It is also important to consider how well the plastic surgeon will be able to perform reconstruction. You can see how this complicated decision is best made by a team of specialists.
If surgery is an option, the surgeon's goal is usually to remove the entire tumor and some healthy tissue around it (this is referred to as achieving clean or negative margins). In some cases, lymph nodes may be removed for further evaluation by the pathologist.
Depending on where the tumor is located and its size, the surgery can be very complex. The plastic surgeon may use skin flaps or prosthetic (man-made) bones to replace those affected by the tumor. The surgery may affect the patient's ability to chew, swallow, speak, hear, or smell, and it may drastically change their facial appearance, either temporarily or permanently. All patients and their families should talk extensively with the healthcare team before surgery and have a complete understanding of what to expect. This can be a very complicated discussion, so no question should be considered too dumb to ask!
Radiation is the use of high-energy x-rays to kill the tumor. This treatment is very complex and should be performed by a radiation team trained in this specialty. Radiation can be given by two different ways: external beam (from a machine outside the body) or brachytherapy (also called internal radiation, from an internally implanted radioactive source).
External beam radiation is administered by a machine called a linear accelerator. The machine points beams of radiation from many angles towards the tumor. The treatment only takes about 15-20 minutes, but is given 5 days a week for 6-8 weeks. It is critical to be certain that you are treating the same spot each day, so a customized mask device is made and employed to maintain the head in the same position each day. Unfortunately, in attempting to target all of the cancer, the radiation also hits nearby healthy cells, leading to side effects including: sore mouth/throat (mucositis), skin burns, painful swallowing, and dry mouth or nose. External beam radiation is the most commonly used form of radiation for head and neck cancers.
Brachytherapy involves implanting a radioactive material (the source) in the tumor and/or around the tumor site. This source slowly releases the radiation over time, delivering it to a small area of tissue. By treating only a small area, side effects are decreased, but this can also increase the likelihood that the cancer may return. For this reason, the treatment is not good for patients with a high risk of recurrence. Unlike external radiation, these patients are "radioactive" while the source is in place, and patients' friends and family can only spend a few minutes a day close to them (within about 5 feet). This can be a problem if the patient cannot care for himself or herself, so proper patient selection is necessary for everyone's safety. Internal radiation is most often used in treating cancers of the lip, oral cavity, and oropharynx.
Chemotherapies are medications used to kill cancer cells and are used in more advanced tumors of the head and neck. Chemotherapy can be given before surgery to shrink a tumor and thus make it easier to remove. This is called neoadjuvant chemotherapy. Chemotherapy that is given after surgery is called adjuvant chemotherapy. Some of the commonly used chemotherapies include: cisplatin, fluorouracil, etoposide, carboplatin and gemcitabine.
Chemotherapy is commonly given in conjunction with radiation therapy. This is referred to as chemoradiation therapy. In this case, the chemotherapy serves two purposes: to treat the cancer cells and to make the radiation work better. This latter effect is called radiosensitization, which means that the cells are made more sensitive to radiation damage in the presence of relatively low doses of the chemotherapy. The problem is that healthy cells are also sensitized, making the side effects more severe than with radiation alone. Chemoradiotherapy has been shown to improve the likelihood that the surgeon will be able to preserve the voice box in laryngeal cancers. It has also been shown to improve survival over chemotherapy alone, but this therapy comes with more toxicity. The most common toxicities experienced by patients receiving chemoradiation are: low blood counts (white and red blood cells), mucositis, mouth sores and difficulty swallowing. This therapy is not the best choice for all patients, particularly those who are not able to tolerate the side effects; but in those that can be supported through the treatment, this is the standard of care. Researchers have not determined which is the best chemoradiotherapy or chemotherapy regimen, but future clinical trials will attempt to determine this.
Researchers have found that 80-90% of squamous cell head and neck cancers have an "overexpression" of the epidermal growth factor receptor (EGFR). This means they produce too many of these receptors, which could be a key factor in their growth. In turn, medications were developed that can block these receptors, hopefully slowing the tumor's growth. The two EGFR inhibitors most commonly used in head and neck cancers are cetuximab and gefitinib. In clinical trials, cetuximab resulted in a 10% improvement in survival 3 years after diagnosis.
Clinical trials have played and continue to play an important role in the treatment of head and neck cancers. The treatments we have today were refined through clinical trials, and many new avenues continue to be explored. Talk with your physician about current clinical trials for head and neck cancers in your area or visit our clinical trials matching service.
The treatment of head and neck cancers can have a significant impact on the patient. Nutritional status is often affected by therapy, and patients often need to be fed through a tube placed in their stomachs (called a PEG or ‘G' tube). In most cases, this is only temporary. For other patients, difficulty swallowing, mucositis (sore mouth and throat), loss of taste, or a lack of saliva production may make eating difficult or impossible. It is important that patients be followed closely by a dietitian to support them in food and supplement choices and to maintain good nutritional status. If necessary, a speech and swallowing specialist can evaluate a person's ability to swallow safely, without choking or inhaling food.
Social workers can help with the financial burden, handling family responsibilities and accessing resources. Psychologists may be needed to help in dealing with the changes in body image and the patient's role in the family. When speech is affected, speech therapists can help regain function or find alternative ways of communicating. Nurses and physicians can offer help in dealing with side effects and pain management.
Follow-up visits with the oncologist(s) will generally be done every four to six weeks for the first year, every two months for the second year, every three months for the third year, every six months for the fourth and fifth years, and annually after that. A chest x-ray may be performed once a year. In some cases, CAT scans or PET scans are used to evaluate for recurrence of the cancer. For patients whose thyroid gland was in the radiation field, thyroid levels should be checked periodically as they may develop a deficiency (hypothyroidism) and require medication to treat this condition.
If a person is still smoking after treatment, he or she should be encouraged and supported to quit. Patients who continue to smoke are at a significantly increased risk of developing a recurrence or a second cancer, either in the head and neck or elsewhere.
If a patient develops a recurrence, treatment is dependent on the extent of the cancer, what treatments were previously used, and the health status of the patient. The same therapies are typically used (surgery, chemotherapy and radiation), although the drug, dosage, or site of radiation may be different.
This article is meant to give you a better understanding of head and neck tumors. Use this knowledge when meeting with your physician, making treatment decisions, and continuing your search for information. You can learn more about head and neck cancers on OncoLink through the related links on the left.
Additional Information may be found at these sites:
American Speech-Language-Hearing Association: Great information about laryngeal and oral cancers and speech and swallowing specialists.
References & Further Reading
Abeloff, M., Armitage, J., Niederhuber, J., Kastan, M. & McKenna, G. (Eds.): Clinical Oncology (2004). Elsevier, Philadelphia, PA.
The American Cancer Society. Facts and Figures. www.cancer.org
Cady, J. (2007) Nutritional support during radiotherapy for head and neck cancer: the role of prophylactic feeding tube placement. Clinical Journal of Oncology Nursing. 11(6):875-80.
Chan ATC (2005) Head and neck cancer: treatment of nasopharyngeal cancer. Annals of Oncology 16(supplement 2):265-268.
Greene, FL et al. (2002) AJCC Cancer Staging Manual, 6 th edition. (American Joint Committee on Cancer) Springer-Verlag, New York.
Licitra, L, Locati, LD & Bossi, P (2004) Head and neck cancer. Annals of Oncology 15 (supplement 4):267-273.
Posner M. Evolving strategies for combined-modality therapy for locally advanced head and neck cancer. Oncologist. 12(8):967-74, 2
Salama, JK et al. (2007) Chemoradiotherapy for locally advanced head and neck cancer. Journal of Clinical Oncology. 25(26):4118-26.
Seiwert, TY & Cohen, EEW (2005) State-of-the-art management of locally advanced head and neck cancer. British Journal of Cancer 92:1341-1348.
Sturgis, EM & PM Cinciripini (2007) Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 110(7):1429-35.